

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

INSIDE INFORMATION AND RESUMPTION OF TRADING

This announcement is issued by CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company announces that its subsidiaries in Shijiazhuang City, Hebei Province have received the 《石家莊市大氣污染防治調度令》 (Shijiazhuang City Air Pollution Prevention Scheduling Order) (the “**Order**”) issued by Shijiazhuang City Air and Water Pollution Prevention Command Office (石家莊市大氣和水污染防治指揮辦公室) dated 18 November 2016. The Order states that according to the 《石家莊市利劍斬污行動實施方案》 (Shijiazhuang City Prevention of Pollution Implementation Measures) and the requirements of the Shijiazhuang municipal government, the Shijiazhuang municipal government has decided to implement strict regulatory/controlling measures on the industrial enterprises in Shijiazhuang, particularly on enterprises in the key industries including pharmaceutical, cement, foundry, iron and steel, coal-electricity, coking and boiler. The Order requires all the pharmaceutical enterprises in Shijiazhuang city to suspend production and not to resume production unless approved by the Shijiazhuang municipal government.

The Group has been actively cooperating with the government on environmental protection work and is making an application to the Shijiazhuang municipal government for permission to continue its normal pharmaceutical production in Shijiazhuang. The sales of the Group’s products can be fulfilled in the short term out of its inventories, and no material adverse effect is

expected on the Group's business conditions in the near future. The Company will make further announcement(s) to update the shareholders and investors on the above matter, if required and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

At the request of the Company, trading in the shares in the Company on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") was halted from 9:00 a.m. on 21 November 2016 pending the release of this announcement. Application has been made by the Company to the Stock Exchange for resumption of trading in the shares in the Company with effect from 9:00 a.m. on 22 November 2016.

By Order of the Board
CSPC Pharmaceutical Group Limited
CHAK Kin Man
Executive Director

Hong Kong, 21 November 2016

As at the date of this announcement, the board of directors of the Company comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu and Mr. LU Hua as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.